Abstracts tagged "osteoporosis and risk"

Abstract Number: 2308 • 2018 ACR/ARHP Annual Meeting
Abaloparatide for Risk Reduction of Nonvertebral and Vertebral Fractures in Postmenopausal Women with Osteoporosis: A Network Meta-Analysis
Jean Yves Reginster¹, Florence Bianic², Rosanne Campbell², Monique Martin², Setareh A. Williams³ and Lorraine A Fitzpatrick³, ¹Université de Liège, Liège, Belgium, ²inVentiv Health, London, United Kingdom, ³Radius Health, Inc., Waltham, MA
Background/Purpose: To assess the relative efficacy of abaloparatide compared with other osteoporosis treatment options (alendronate, denosumab, ibandronate, raloxifene, risedronate, romosozumab, strontium ranelate, teriparatide, zoledronic acid).…
Abstract Number: 2809 • 2018 ACR/ARHP Annual Meeting
Skeletal Benefit/Risk of Long-Term Denosumab Therapy: A Virtual Twin Analysis of Fractures Prevented to Skeletal Safety Events Observed
Serge Ferrari¹, E. Michael Lewiecki², Peter W. Butler³, David L Kendler⁴, Nicola Napoli⁵, Shuang Huang³, Daria B Crittenden³, Nicola Pannacciulli³, E.S. Siris⁶ and Neil Binkley⁷, ¹Geneva University Hospital, Geneva, Switzerland, ²New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ³Amgen Inc., Thousand Oaks, CA, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵Campus Bio-Medico University of Rome, Rome, Italy, ⁶Columbia University Medical Center, New York, NY, ⁷University of Wisconsin–Madison Osteoporosis Clinical Center and Research Program, Madison, WI
Background/Purpose: Osteoporosis is a chronic disease, yet skeletal safety events—atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ)—remain a concern with long-term treatment. Ten…
Abstract Number: 230 • 2014 ACR/ARHP Annual Meeting
Risk Factors That Predict Poor Bone Health in Those Aged over 75 Years – a Cross Sectional Study
James Fowler^1,2, Christopher Varley³, Alexander Oldroyd³ and Marwan Bukhari³, ¹Faculty of Health and Medicine, Lancaster Univeristy, Lancaster, United Kingdom, ²University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, United Kingdom, ³Lancaster Medical School, Lancaster University, Lancaster, United Kingdom
Background/Purpose .No studies have been conducted into the over 75 population specifically to assess the risk factors that predict BMD loss. The Framingham Osteoporosis Study…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].